SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.

Shoag, Jonathan; Liu, Deli; Blattner, Mirjam; Sboner, Andrea; Park, Kyung; Deonarine, Lesa; Robinson, Brian D; Mosquera, Juan Miguel; Chen, Yu; Rubin, Mark Andrew; Barbieri, Christopher E (2018). SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. Journal of clinical investigation, 128(1), pp. 381-386. American Society for Clinical Investigation 10.1172/JCI96551

Preview

Text JCI96551.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (9MB) | Preview

Nearly 50% of prostate cancers harbor gene fusions that lead to overexpression of the transcription factor ERG, while a mutually exclusive 10% of prostate cancers harbor recurrent mutations in the gene encoding the E3 ubiquitin ligase SPOP. Recent reports suggest that SPOP acts as a ubiquitin ligase for ERG and propose that ERG stabilization is the oncogenic effector of SPOP mutation. Here, we used human prostate cancer samples and showed that the vast majority of human SPOP-mutant cancers do not express ERG. Comparison of SPOP-mutant and ERG-fusion organoid models showed evidence of divergent, rather than common, transcriptional programs. Furthermore, expression of prostate cancer-associated SPOP mutations in genetically engineered mouse models of SPOP-mutant prostate cancer did not result in the expression of ERG protein in histologically normal prostate glands, high-grade prostatic intraepithelial neoplasia, invasive adenocarcinoma, or prostate organoids. In summary, we found no evidence that ERG is an effector of SPOP mutation in human prostate cancer or mouse models.

Interest & Impact

Downloads

209 since deposited on 08 Mar 2018
24 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item